Trovagene to unveil key study data at APAC Prostate Cancer Conference
Category: #health  By Mateen Dalal  Date: 2019-08-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Trovagene to unveil key study data at APAC Prostate Cancer Conference
  • Data from the Phase 2 Onvansertib clinical trial will be presented at the 20th Prostate Cancer Conference.
     
  • The trial assesses the efficacies of Onvansertib on patients with Metastatic Castration-Resistant Prostate Cancer.

Trovagene, a clinical-stage oncology therapeutics firm making drugs that specifically target cell division (mitosis), to treat several types of cancer, including leukemia, colorectal and prostate, reportedly announced that latest clinical data from Onvansertib Phase 2 trial, in combination with prednisone/Zytiga® (abiraterone acetate), in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be shown as an oral poster in the Asia-Pacific Prostate Cancer Conference.

This would be the 20th Prostate Cancer Conference. The conference will be held in Melbourne, Australia from 23rd Aug to 26th August of this year.

The information will be given in a moderated, oral poster session. The moderate poster session would take place on 24th of August in the afternoon at 1:00 (AEDT). Trovagene Poster Presentation would be titled as a Phase 2 Study of a combination of Onvansertib, a PLK1 Inhibitor, with Prednisone and Abiraterone in patients suffering from Metastatic Castration-Resistant Prostate Cancer (mCRPC).

The Abstract number of this presentation is 1044 and the moderate poster session would be coming under the Clinical Urology segment of the presentation. The presentation will be held in the Goldfields Exhibition.

About Trovagene Inc.:

Trovagene is a renowned clinical-stage, oncology therapeutics firm, having a precision cancer medicine based approach to make drugs that specifically target mitosis (cell division) for the treatment of several types of cancer including solid tumors, lymphomas, and leukemias.

Trovagene has proprietary technology and intellectual property that allows the company to examine the circulating tumor DNA (ctDNA) and other clinically actionable markers to recognize patients that are likely to showcase a positive response to specific cancer treatments. Trovagene is aiming to continue the vertical integration of its tumor genomics technology with development of its targeted cancer therapeutics.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Roches risdiplam meets primary endpoint results in phase 3 trial
Roches risdiplam meets primary endpoint results in phase 3 trial
By Mateen Dalal

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, affecting approx. 1 in 6,000 babies born globally each year. Numerous healthcare companies throughout the world are putting their best foot forward to develop an effective ...

Disney+ all set for a March 2020 launch in the United Kingdom
Disney+ all set for a March 2020 launch in the United Kingdom
By Mateen Dalal

The entertainment behemoth is launching its much-awaited streaming platform.   Release of more than 300 movies is on the cards. Disney has finally asserted that new streaming service Disney+ will be rolled out soon in the U.K. Disney+ goes...

AB Science receives Orphan Drug Designation from the FDA for AB8939
AB Science receives Orphan Drug Designation from the FDA for AB8939
By Mateen Dalal

AML (acute myeloid leukemia), a severe, life-threating disease that is one of the most common causes of cancer-related death. Common treatment options for this condition includes stem-cell transplants, chemotherapy and other drug therapy. However, wi...